Secukinumab exerts its anti-inflammatory effect by targeting IL-17, a cytokine that plays an essential role in both the etiology of chronic skin inflammation in psoriasis and the etiology of atherosclerosis. This evidence concerns the gene IL17A and atherosclerosis.